The Government Accountability Office said it will investigate potential abuses of the orphan drug program, which offers incentives to drugmakers to develop medicines for rare diseases.
Marathon, maker of an expensive treatment for Duchenne muscular dystrophy, sells the drug for $140 million in cash and stock to PTC Therapeutics.
A growing number of patients fail to fill prescriptions because the cost of cancer drugs is too high.
A Kaiser Permanente pain management program in Southern California aims to help patients taper off addictive painkillers. Some doctors and patients see it as a godsend; others complain that patients have been cut off medications they need.
Blue Shield of California is hoping to steer consumers to “preferred” pharmacies where drugs are cheaper and copays lower.
Two Democratic congressmen met with President Trump to seek his support for a bill to expand the government’s ability to negotiate drug prices, but it’s not clear it would have much impact or will gain support.
Hundreds of drug brands are being made in giant contract facilities. When a plant shuts down, a widespread drain on supply can result.
An aging writer discovers there are worse things than going bald after examining the side effects of a popular hair loss drug purportedly used by President Donald Trump.
Nadie entiende mejor que estos especialistas en envejecimiento cómo múltiples problemas médicos interactúan en las personas mayores, y cómo pueden afectar su calidad de vida. Sin embargo, su papel en el sistema de atención de salud sigue siendo poco comprendido y sus conocimientos, subutilizados.
Aging adults with complex needs can get special assistance from doctors trained as geriatricians.
Some terminal patients, typically high-dose opioid users, who choose to end their lives have taken many hours, even days, to die.
The woman set to run the federal Centers for Medicare & Medicaid Services told senators last week that maternity coverage should be optional in individual and small group plans. But other services could also be left on the cutting room floor.
Former FDA Commissioner Dr. Robert Califf shares his views about drug approvals, regulations and safety concerns after stepping down from the giant agency.
After hearing complaints about its high price, Marathon Pharmaceuticals is pausing the launch of an $89,000 drug for a rare disease.
Citing a Kaiser Health News investigation, Senate Judiciary Committee Chairman Chuck Grassley vows to examine the orphan drug program and possible fixes.
Prescription pain pills are strong sellers in this southeastern Kentucky region that’s long struggled with high rates of joblessness and poor health.
Luke Whitbeck’s life was saved by a rare disease drug, but it costs $300,000 a year.
Despite questions about Lupron’s lasting side effects and minimal study into its safety, the FDA sped approval of the drug to market. Years later, some young women are still living with the consequences.
An expert geriatrician says the benefits for the patient, such as alleviating pain and maintaining independence, must be weighed against the possible risks. Her motto: ‘start low and go slow.’
Wood, who chairs the Assembly Health Committee, lays out his priorities for 2017.